Having demonstrated the downregulation of surface PD‐L1 expression by BRAF inhibition, we hypothesized that vemurafenib should trigger increased activation of T cells interacting with vemurafenib‐pretreated melanoma cells. The gene discussed is BRAF; the disease is melanoma.